Dr Joann Suzich | Vice President of Infectious Disease and Vaccines Research
MedImmune Ventures Inc.

Dr Joann Suzich, Vice President of Infectious Disease and Vaccines Research, MedImmune Ventures Inc.

JoAnn Suzich, Ph.D. serves as Vice President of Infectious Disease and Vaccines Research, and is responsible for overseeing MedImmune’s research on antibodies and antibody-like molecules for the prophylaxis and treatment of infections, as well as novel biologics for the treatment of cancer.    She has been involved in many key development programs at MedImmune, including Synagis® (palivizumab) and the virus-like particle technology that is the basis of the human papillomavirus (HPV) vaccines used to prevent cervical cancer.  Current areas of interest include respiratory viruses (RSV, influenza), serious bacterial infections (S. aureus, P. aeruginosa, K. pneumoniae), and cancer vaccine & oncolytic virus technologies.


Agenda Day 1 @ 4:45

Is it time to start considering antibodies as an alternative to vaccines?

  • Synagis® (palivizumab) is the only monoclonal antibody (MAb) currently marketed for prevention of an infectious disease
  • Advances in biologics technology has allowed the development of a highly potent MAb that is being investigated as a vaccine surrogate to protect all infants from RSV disease
  • Are there other diseases, for which vaccine development has been difficult, where MAbs might fill the void?

back to speakers